QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-neutral-on-cogent-biosciences-raises-price-target-to-34

Baird analyst Colleen Kusy maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $14 to...

 leerink-partners-maintains-outperform-on-cogent-biosciences-raises-price-target-to-50

Leerink Partners analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price tar...

 cogent-biosciences-announces-200m-senior-notes-offering-200m-common-stock-offering

Cogent Biosciences, Inc. ("Cogent") (Nasdaq: COGT), a biotechnology company focused on developing precision therapies f...

 cogent-biosciences-lead-cancer-drug-cuts-disease-progression-or-death-risk-by-50-in-stomach-cancer-trial

Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIS...

 cogent-biosciences-combination-of-bezuclastinib-plus-sunitinib-in-phase-3-peak-study-reaches-median-progression-free-survival-of-165-months-company-on-track-to-submit-new-drug-application-to-us-fda-for-bezuclastinib-in-intolerant-gastrointestinal-stromal-tumors

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defi...

 cogent-biosciences-files-for-mixed-shelf-offering-size-not-disclosed

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-cogent-biosciences-maintains-21-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $21 price ...

 cogent-biosciences-announces-updated-preclinical-data-from-the-cos-potent-and-selective-pan-krason-inhibitor-in-a-poster-presentation-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-says-poster-highlights-that-cgt1815-demonstrates-superior-efficacy-in-krasg12d-and-krasg12v-tumor-growth-inhibition-studies-when-compared-to-rmc-6236

Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defin...

 jp-morgan-maintains-overweight-on-cogent-biosciences-raises-price-target-to-44

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from ...

 stifel-initiates-coverage-on-cogent-biosciences-with-hold-rating-announces-price-target-of-16

Stifel analyst Laura Prendergast initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Hold rating and announces Pri...

 raymond-james-initiates-coverage-on-cogent-biosciences-with-strong-buy-rating-announces-price-target-of-30

Raymond James analyst Chris Raymond initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Strong Buy rating and anno...

 guggenheim-maintains-buy-on-cogent-biosciences-raises-price-target-to-20

Guggenheim analyst Charles Zhou maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $17 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION